ArticleBlood advances2023

Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions.

Ajay Major et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.